Epitalon
Also known as: Epithalon · Epithalamin · AEDG · Ala-Glu-Asp-Gly
Research focus
Pineal / circadian signaling; telomere biology; age-related endocrine decline.
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
Theoretical
Origin
Synthesized by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s, based on analysis of the polypeptide pineal extract Epithalamin. Patented in Russia and listed as a synthetic analog of a naturally occurring pineal peptide fraction.
Plain-language summary
Epitalon is a four-amino-acid peptide designed in Soviet-era gerontology research to mimic a fraction of natural pineal-gland extract. Russian studies report anti-aging signals in cell cultures and rodents — longer lifespans, restored melatonin rhythm, and lengthened telomeres in some experiments. The work has almost no replication outside Russia. Human clinical data is limited to small, often unblinded trials conducted by the original research group.
Claimed mechanism (as reported)
Published research proposes that Epitalon binds to specific regions of DNA and influences gene expression, upregulates telomerase activity in cultured somatic cells, and normalizes melatonin rhythm in aged animals. Mechanism remains an area of active investigation; the DNA-binding model is primarily supported by in-silico and in-vitro work from the Khavinson group.
Evidence summary
Strong preclinical record in rodents (lifespan extension, tumor incidence reduction, melatonin normalization). Limited human data — mostly open-label geriatric studies from a single research group. No large, independently-replicated randomized controlled trials exist in peer-reviewed English-language literature as of 2026.
What the research reports
Peptide Epitalon enhances resynchronization of rhythmic processes in elderly subjects
Grade CKhavinson VKh, Korkushko OV, Shatilo VB et al. · Bulletin of Experimental Biology and Medicine (multiple publications 2000–2012) · 2000–2012
Reported finding: Administration over 10–20 days reportedly normalized melatonin secretion patterns, improved circadian indicators, and reduced markers of oxidative stress in older adults. Reported without independent replication.
Sample: Typically n=20–100 per study
Methodology: C — small open-label geriatric cohorts, single research group, limited blinding
Limitations: Small samples, unblinded, single-group studies, outcomes not always consistent with current geroscience endpoint standards.
Effect of Epithalon on the lifespan increase and spontaneous tumor incidence in female Swiss-derived SHR mice
Grade BAnisimov VN, Khavinson VKh et al. · Mechanisms of Ageing and Development · 2000–2003
Reported finding: Epithalon administration was associated with increased mean lifespan and reduced incidence of spontaneous mammary tumors in aged mice.
Sample: 100+ animals per arm
Methodology: B (animal) — long-duration rodent lifespan study
Limitations: Rodent-only; translation to human endpoints unproven.
Peptide regulation of gene expression and protein synthesis (review)
Grade DKhavinson VKh, Malinin VV et al. · Bulletin of Experimental Biology and Medicine; Neuroendocrinology Letters · 2002–2017
Reported finding: Propose a 'peptide bioregulator' mechanism wherein short peptides bind specific DNA regions and influence transcription. Remains a minority model in the broader peptide pharmacology literature.
Sample: N/A
Methodology: D — mechanistic review from primary investigators (not independent)
Limitations: Author-overlap with virtually all Russian Epitalon literature creates an independence-of-review concern.
Administration reported in studies
Published human studies typically describe intramuscular injection of 5–10 mg per course, administered over 10–20 days, once to twice per year. Some studies describe intranasal and subcutaneous routes. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPS.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
No serious adverse events have been reported in published studies. Sample sizes and follow-up durations are modest, so rare or long-term harms cannot be ruled out. No pharmacokinetic, reproductive, or oncologic safety data meeting modern regulatory standards has been published in English-language literature.
US legal status
Not FDA-approved. Not on the 503A compoundable bulk substances list. Not legally compoundable for human clinical use in the United States. Sold online only as 'research chemical' — vendors in that channel are unregulated and not verified by TPS.
Open research questions
- ? Do the telomerase-related findings replicate in independent, non-Khavinson-affiliated laboratories?
- ? Are the geriatric circadian effects reproducible in randomized, double-blind conditions?
- ? What are the long-term oncologic safety data in humans beyond the original Russian cohorts?
- ? Is there a validated pharmacokinetic profile across intramuscular, intranasal, and subcutaneous routes?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →